Doxorubicin

Generic Name: Doxorubicin

Brand Names: Adriamycin, Doxil, Myocet, Caelyx pegylated liposomal, Zolsketil pegylated liposomal, Myocet liposomal (previously Myocet), Celdoxome pegylated liposomal

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₂₉NO_₁₁

CAS Number: 23214-92-8

Unique Ingredient Identifier: 80168379AG

Background: Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970. Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its deta...

Indication: Doxorubicin is indicated for the treatment of neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin and non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue and bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinom...

Associated Conditions: AIDS-related Kaposi's Sarcoma, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Advanced Endometrial Cancer, Advanced Ovarian Cancer, Breast Cancer, Hodgkin's Lymphoma, Metastatic Bone Sarcomas, Metastatic Breast Cancer, Metastatic Soft Tissue Sarcoma, Metastatic Thyroid Cancer, Metastatic Urothelial Cancer, Multiple Myeloma (MM), Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Sezary Syndrome, Waldenström's Macroglobulinemia (WM), Advanced Thymoma, Advanced uterine sarcoma, Metastatic Bronchogenic Carcinoma, Metastatic Gastric carcinoma, Metastatic Neuroblastoma, Metastatic Ovarian carcinoma, Metastatic Wilms' tumor

Associated Therapies: -

Clinical Trials

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

Phase 2

Recruiting

Conditions: Stage 1 cT1b-T1cN0M0
Triple Negative Breast Cancer

Interventions: Drug: Carboplatin
Drug: Paclitaxel
Drug: Pembrolizumab
Drug: Doxorubicin
Drug: Cyclophosphamide

First Posted Date: 2024-03-19

Last Posted Date: 2024-12-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 28

Registration Number: NCT06318897

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Phase 3

Not yet recruiting

Conditions: Relapsed or Refractory Follicular Lymphoma

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Liso-cel
Drug: Vincristine
Drug: Rituximab
Drug: Prednisone
Drug: Bendamustine
Drug: Lenalidomide

First Posted Date: 2024-03-15

Last Posted Date: 2024-03-15

Lead Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Target Recruit Count: 300

Registration Number: NCT06313996

Pharmacogenetic of Doxorubicin in HCC.

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Doxorubicin

First Posted Date: 2024-03-15

Last Posted Date: 2024-03-28

Lead Sponsor: Rehab Werida

Target Recruit Count: 81

Registration Number: NCT06313047

Locations: 🇸🇦
King Abdullah bin Abdulaziz University Hospital, Riyadh, Saudi Arabia

The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients.

Phase 2

Not yet recruiting

Conditions: Minimally Invasive Surgical Procedures
Chemotherapy, Adjuvant
Peritoneal Metastases
Gastric Cancer

Interventions: Drug: Cisplatin
Drug: Doxorubicin

First Posted Date: 2024-03-06

Last Posted Date: 2024-03-06

Lead Sponsor: Odense University Hospital

Target Recruit Count: 264

Registration Number: NCT06295094

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇫🇷
University Hospital Lille, Lille, France
🇩🇪
Charité, University of Berlin, Berlin, Germany

and more 2 locations

Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

Phase 3

Recruiting

Conditions: Follicular Lymphoma

Interventions: Drug: Mosunetuzumab
Drug: Rituximab
Drug: Obinutuzumab
Drug: Bendamustin
Drug: Cyclophosphamide
Drug: Lenalidomide
Drug: Doxorubicin
Drug: Vincristin
Drug: Prednisone

First Posted Date: 2024-02-28

Last Posted Date: 2024-10-11

Lead Sponsor: The Lymphoma Academic Research Organisation

Target Recruit Count: 790

Registration Number: NCT06284122

Locations: 🇫🇷
HOPITAL HENRI MONDOR - Unité Hémopathies Lymphoïdes, Créteil, France
🇫🇷
GUSTAVE ROUSSY CANCER CAMPUS GRAND PARIS - Département Médecine Oncologique, Villejuif, France
🇫🇷
CH ANNECY GENEVOIS - SITE D'ANNECY - Service Hématologie, Pringy, France

and more 46 locations